Rexahn Pharmaceuticals (RNN)
Rexahn Pharmaceuticals Days Sales Outstanding
View RNN Days Sales Outstanding with YCharts Pro.
Access these YCharts Pro features:
Export any data you want
Save any chart as an image
Utilize advanced screener power
View 30 years of financial history
over 90 advanced calculations
Enjoy an advertising free experience
About Days Sales Outstanding
The average number of days it takes for a company to collect outstanding receivables.
Learn More
You may also be interested in these RNN related companies
RNN News
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anti-Cancer Compound RX-3117
May 30, 8:00AM Business Wire
May 30, 8:00AM Business Wire
Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA
May 08, 8:02AM Benzinga
May 08, 8:02AM Benzinga
Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds
Apr 30, 8:00AM Business Wire
Apr 30, 8:00AM Business Wire
$RNN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3XOX
about 35 days ago by MarketBrief
about 35 days ago by MarketBrief
Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting
Mar 27, 8:00AM Business Wire
Mar 27, 8:00AM Business Wire
Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117
Mar 13, 8:02AM Benzinga
Mar 13, 8:02AM Benzinga
Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds
Jan 25, 8:00AM Benzinga
Jan 25, 8:00AM Benzinga
Rodman & Renshaw Changes Rating on Rexahn Pharmaceuticals to Market Perform
Jan 18, 12:44PM Benzinga
Jan 18, 12:44PM Benzinga
Rexahn Pharmaceuticals (RNN) Receives Approval in Europe to Conduct a First-in-Human Trial of RX-3117
Jan 18, 8:03AM Street Insider
Jan 18, 8:03AM Street Insider
Drug Candidates From Rexahn and Elite Pharmaceuticals Look to Pass Key Tests
Nov 09, 8:16AM Marketwire
Nov 09, 8:16AM Marketwire
Rexahn Pharmaceuticals (RNN) Offers Results from Phase II Trial of Serdaxin for Major Depressive Disorder
Nov 04, 8:26AM Street Insider
Nov 04, 8:26AM Street Insider
Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin® as Treatment for Major Depressive Disorder
Nov 04, 8:00AM Business Wire
Nov 04, 8:00AM Business Wire
Rexahn Pharmaceuticals granted U.S. patent for isoquinolinamine compounds
Oct 12, 8:01AM FlyOnTheWall
Oct 12, 8:01AM FlyOnTheWall
Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds
Oct 12, 8:00AM Business Wire
Oct 12, 8:00AM Business Wire
Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin®
Oct 03, 8:00AM Business Wire
Oct 03, 8:00AM Business Wire
Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
Sep 08, 8:00AM Business Wire
Sep 08, 8:00AM Business Wire
Rexahn Pharmaceuticals announces patent for neurotherapeutic compositions
Aug 08, 9:03AM FlyOnTheWall
Aug 08, 9:03AM FlyOnTheWall
$RNN http://chart.ly/bxxaome Do not like the Company at all; however they have done some excellent P&D. very tight range.
about 307 days ago by Wiserguy1971
about 307 days ago by Wiserguy1971
sold the $RNN I've been holding for at least a month at 1.21 for small loss. don't like the large shelf offering
about 343 days ago by LitheLyricist
about 343 days ago by LitheLyricist
RT @ABtrader $RNN sees completing Trial, announcing Prelim Results before Yr End = Should see some big action today.
about 344 days ago by epollux
about 344 days ago by epollux
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| RNN | 0.408 | +0.00 | +0.00% | 38.90M |
| RNIN | 0.76 | +0.01 | +1.33% | 17.46M |
| RNF | 23.85 | +0.45 | +1.92% | |
| RNET | 15.33 | +0.13 | +0.86% | 234.69M |
| RNE | 13.72 | -0.25 | -1.79% | |
| RMTR | 1.86 | -0.10 | -5.10% | 69.24M |
| RMT | 8.70 | -0.02 | -0.23% | |
| RMKR | 0.65 | +0.02 | +3.14% | 17.43M |
| RMD | 30.70 | -0.42 | -1.35% | 4.487B |
| RMCF | 10.45 | -0.01 | -0.10% | 64.05M |